Advertisement

Subcellular, Cellular and Organ Pathology of Fabry Disease

  • Milan EllederEmail author
Chapter

Abstract

Survey of the known structural alterations is presented at the subcellular, cellular and organ levels with an attempt to correlate them with the primary enzyme catalytic defect and with pathways representing the main substrate influx into the deficient lysosomal system; the latter of which has turned out to be largely unknown. All these structural changes are presented as a basis of the known functional sequels responsible for the altered biology of the storage lysosomal system and of storage affected cells and which, ultimately, lead to cell death, and organ destruction and failure. Cell types expressing lysosomal storage are listed, some of which are less well known, while others are suggested as candidates for future studies.

Keywords

Fabry disease α galactose lipid conjugates Lipid storage Storage lysosome Cell pathology Organ pathology 

Notes

Acknowledgement

Bulk of the studies was supported by a research project of the Ministry of Education Youth and Sports (Grant No. MSM 0021620806). Technical assistance in manuscript preparation by Eva Horáková, perfect laboratory work of Irena Knesplová, Marie Kolářová and Lenka Kryšpinová and are greatly appreciated. The author thanks also to Dr. Tom Secrest for language text editation

References

  1. 1.
    Maloney MD, Lingwood CA (1994) CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med 180(1):191–201PubMedCrossRefGoogle Scholar
  2. 2.
    Ledvinova J, Poupetova H, Hanackova A, Pisacka M, Elleder M (1997) Blood group B glycosphingolipids in alpha-galactosidase deficiency (Fabry disease): influence of secretor status. Biochim Biophys Acta 1345(2):180–187PubMedCrossRefGoogle Scholar
  3. 3.
    Wherrett JR, Hakomori SI (1973) Characterization of a blood group B glycolipid, accumulating in the pancreas of a patient with Fabry’s disease. J Biol Chem 248(9):3046–3051PubMedGoogle Scholar
  4. 4.
    Linthorst GE, Folman CC, Aerts JM, Hollak CE (2003) Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency). Blood Cells Mol Dis 31(3):324–326PubMedCrossRefGoogle Scholar
  5. 5.
    Bodary PF, Shayman JA, Eitzman DT (2007) Alpha-galactosidase A in vascular disease. Trends Cardiovasc Med 17(4):129–133PubMedCrossRefGoogle Scholar
  6. 6.
    Desnick RJ, Ioannou YA, Eng CM (2001) α-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774Google Scholar
  7. 7.
    Cuervo AM (2004) Autophagy: many paths to the same end. Mol Cell Biochem 263(1–2):55–72PubMedCrossRefGoogle Scholar
  8. 8.
    Maxfield FR, McGraw TE (2004) Endocytic recycling. Nat Rev Mol Cell Biol 5(2):121–132PubMedCrossRefGoogle Scholar
  9. 9.
    Kanda A, Nakao S, Tsuyama S, Murata F, Kanzaki T (2000) Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits. Virchows Arch 436(1):36–42PubMedCrossRefGoogle Scholar
  10. 10.
    Zeidner KM, Desnick RJ, Ioannou YA (1999) Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal Biochem 267(1):104–113PubMedCrossRefGoogle Scholar
  11. 11.
    Keslova-Veselikova J, Hulkova H, Dobrovolny R et al (2008) Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Arch 452(6):651–665PubMedCrossRefGoogle Scholar
  12. 12.
    Dvorak AM, Cable WJ, Osage JE, Kolodny EH (1981) Diagnostic electron microscopy. II. Fabry´s disease: use of biopsies from uninvolved skin. Acute and chronic changes involving the microvasculature and small unmyelinated nerves. In: Summers SC, Rosen PP (eds) Pathology annual. Appleton-Century-Crofts, New York, pp 139–158Google Scholar
  13. 13.
    Elleder M, Ledvinova J, Vosmik F, Zeman J, Stejskal D, Lageron A (1990) An atypical ultrastructural pattern in Fabry’s disease: a study on its nature and incidence in 7 cases. Ultrastruct Pathol 14(6):467–474PubMedCrossRefGoogle Scholar
  14. 14.
    Seehafer SS, Pearce DA (2006) You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol Aging 27(4):576–588PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang M, Sun M, Dwyer NK et al (2003) Differential trafficking of the Niemann-Pick C1 and 2 proteins highlights distinct roles in late endocytic lipid trafficking. Acta Paediatr Suppl 92(443):63–73, discussion 45PubMedGoogle Scholar
  16. 16.
    Simon M, Frey H, Gruler H, Bultmann B (1990) Glycolipid storage material in Fabry’s disease: a study by electron microscopy, freeze-fracture, and digital image analysis. J Struct Biol 103(1):40–47PubMedCrossRefGoogle Scholar
  17. 17.
    Shen JS, Meng XL, Moore DF et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95(3):163–168PubMedCrossRefGoogle Scholar
  18. 18.
    Lucke T, Hoppner W, Schmidt E, Illsinger S, Das AM (2004) Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab 82(1):93–97PubMedCrossRefGoogle Scholar
  19. 19.
    Vylet’al P, Hulkova H, Zivna M et al (2008) Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. J Inherit Metab Dis 31(4):508–517PubMedCrossRefGoogle Scholar
  20. 20.
    Shu L, Shayman JA (2007) Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J Biol Chem 282(29):20960–20967PubMedCrossRefGoogle Scholar
  21. 21.
    Thomaidis T, Relle M, Golbas M et al (2009) Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney Int 75(4):399–407PubMedCrossRefGoogle Scholar
  22. 22.
    Elleder M, Stejskal J (1985) Induction of dipeptidylpeptidase IV activity in human renal glomeruli–a histochemical study. Acta Histochem 77(1):75–78PubMedCrossRefGoogle Scholar
  23. 23.
    Settembre C, Fraldi A, Jahreiss L et al (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17(1):119–129PubMedCrossRefGoogle Scholar
  24. 24.
    Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105(8):2812–2817PubMedCrossRefGoogle Scholar
  25. 25.
    Ohshima T, Murray GJ, Swaim WD et al (1997) Alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94(6):2540–2544PubMedCrossRefGoogle Scholar
  26. 26.
    Elleder M (2003) Sequelae of storage in Fabry disease–pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92(443):46–53, discussion 45PubMedGoogle Scholar
  27. 27.
    Utsumi K, Yamamoto N, Kase R et al (1997) High incidence of thrombosis in Fabry’s disease. Intern Med 36(5):327–329PubMedCrossRefGoogle Scholar
  28. 28.
    Heare T, Alp NJ, Priestman DA et al (2007) Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis 30(1):79–87PubMedCrossRefGoogle Scholar
  29. 29.
    Park JL, Whitesall SE, D’Alecy LG, Shu L, Shayman JA (2008) Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35(10):1156–1163PubMedCrossRefGoogle Scholar
  30. 30.
    Gelderman MP, Schiffmann R, Simak J (2007) Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler Thromb Vasc Biol 27(7):e138PubMedCrossRefGoogle Scholar
  31. 31.
    Vedder AC, Biro E, Aerts JM, Nieuwland R, Sturk G, Hollak CE (2009) Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dial Transplant 24(10):3074–3081PubMedCrossRefGoogle Scholar
  32. 32.
    Elleder M (1994) The spleen and storage disorders. In: Cuschieri A, Forbes CD (eds) Disorders of the spleen, 1st edn. Blackwell Scientific Publications, Oxford, pp 151–190Google Scholar
  33. 33.
    Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. Circ Res 97(6):512–523PubMedCrossRefGoogle Scholar
  34. 34.
    Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83(1):253–307PubMedGoogle Scholar
  35. 35.
    Cable WJ, Kolodny EH, Adams RD (1982) Fabry disease: impaired autonomic function. Neurology 32(5):498–502PubMedCrossRefGoogle Scholar
  36. 36.
    Witschel H, Mathyl J (1969) Morphological bases of the specific ocular changes in Fabry’s disease. Klin Monatsbl Augenheilkd 154(4):599–605PubMedGoogle Scholar
  37. 37.
    Kelly MM, Leigh R, McKenzie R, Kamada D, Ramsdale EH, Hargreave FE (2000) Induced sputum examination: diagnosis of pulmonary involvement in Fabry’s disease. Thorax 55(8):720–721PubMedCrossRefGoogle Scholar
  38. 38.
    Rosenberg DM, Ferrans VJ, Fulmer JD et al (1980) Chronic airflow obstruction in Fabry’s disease. Am J Med 68(6):898–905PubMedCrossRefGoogle Scholar
  39. 39.
    Nistal M, Paniagua R, Picazo ML (1983) Testicular and epididymal involvement in Fabry’s disease. J Pathol 141(2):113–124PubMedCrossRefGoogle Scholar
  40. 40.
    Kaesgen U, Goebel HH (1989) Intraepidermal morphologic manifestations in lysosomal diseases. Brain Dev 11(5):338–341PubMedCrossRefGoogle Scholar
  41. 41.
    Bagdade JD, Parker F, Ways PO, Morgan TE, Lagunoff D, Eidelman S (1968) Fabry’s disease. A correlative clinical, morphologic, and biochemical study. Lab Invest 18(6):681–688PubMedGoogle Scholar
  42. 42.
    McCulloch C, Ghosh M (1984) Ultrastructural changes in the cornea and conjunctiva of aheterozygous woman with Fabry’s disease. Can J Ophthalmol 19(4):192–198PubMedGoogle Scholar
  43. 43.
    Baccaglini L, Schiffmann R, Brennan MT, Lancaster HE Jr, Kulkarni AB, Brahim JS (2001) Oral and craniofacial findings in Fabry’s disease: a report of 13 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92(4):415–419PubMedCrossRefGoogle Scholar
  44. 44.
    Tsukada N, Hanu N, Oguchi K, Yanagisawa N, Tsukagoshi H, Hattori H (1980) Fabry’s disease with malocclusion and acromegalic-appearance: clinical and electromicroscopic studies (author’s transl). No To Shinkei 32(3):311–319PubMedGoogle Scholar
  45. 45.
    Takao M, Mori T, Orikasa H et al (2007) Postmortem diagnosis of Fabry disease with acromegaly and a unique vasculopathy. Virchows Arch 451(3):721–727PubMedCrossRefGoogle Scholar
  46. 46.
    Faraggiana T, Churg J, Grishman E et al (1981) Light- and electron-microscopic histochemistry of Fabry’s disease. Am J Pathol 103(2):247–262PubMedGoogle Scholar
  47. 47.
    deVeber GA, Schwarting GA, Kolodny EH, Kowall NW (1992) Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 31(4):409–415PubMedCrossRefGoogle Scholar
  48. 48.
    Witschel H, Meyer W (1968) Fabry’s diseae. Clinical and pathologic studies of a clinical case. Klin Wochenschr 46(6):305–311PubMedCrossRefGoogle Scholar
  49. 49.
    Tome FM, Fardeau M, Lenoir G (1977) Ultrastructure of muscle and sensory nerve in Fabry’s disease. Acta Neuropathol 38(3):187–194PubMedCrossRefGoogle Scholar
  50. 50.
    Barba Romero M-A, Medrano Gonzales F, Gomez Garrido J, Gomez Merino E, Perez Martinez J, Blazquez Cabrera JA (2003) Fabry disease: exceptional cause of rhabdomyolysis? Acta Paediatr Suppl 443:101–102Google Scholar
  51. 51.
    Vedder AC, Cox-Brinkman J, Hollak CE et al (2006) Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 89(3):239–244PubMedCrossRefGoogle Scholar
  52. 52.
    Mayou SC, Kirby JD, Morgan SH (1989) Anderson-Fabry disease: an unusual presentation with lymphadenopathy. J R Soc Med 82(9):555–556PubMedGoogle Scholar
  53. 53.
    Garzuly F, Marodi L, Erdos M et al (2005) Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the alpha-galactosidase A gene. Brain 128(Pt 9):2078–2083PubMedCrossRefGoogle Scholar
  54. 54.
    Okeda R, Nisihara M (2008) An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology 28(5):532–540PubMedCrossRefGoogle Scholar
  55. 55.
    Barbey F, Brakch N, Linhart A et al (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26(4):839–844PubMedCrossRefGoogle Scholar
  56. 56.
    Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP (2002) Arterial remodelling in Fabry disease. Acta Paediatr Suppl 91(439):62–66PubMedCrossRefGoogle Scholar
  57. 57.
    Kalliokoski RJ, Kalliokoski KK, Penttinen M et al (2006) Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis 29(5):660–666PubMedCrossRefGoogle Scholar
  58. 58.
    Moore DF, Altarescu G, Pursley R et al (2002) Arterial wall properties and Womersley flow in Fabry disease. BMC Cardiovasc Disord 2:1PubMedCrossRefGoogle Scholar
  59. 59.
    Kentish JC, Ward JPT (2008) Smooth muscle and the cardiovascular and lymphatic systems. In: Standring S (ed) Gray´s anatomy the anatomical basis of clinical practice. Elsevier, London, pp 127–144Google Scholar
  60. 60.
    Altarescu G, Moore DF, Pursley R et al (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32(7):1559–1562PubMedCrossRefGoogle Scholar
  61. 61.
    Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251(5):564–570PubMedCrossRefGoogle Scholar
  62. 62.
    Kalliokoski RJ, Kalliokoski KK, Sundell J et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28(4):563–573PubMedCrossRefGoogle Scholar
  63. 63.
    Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104(13):1506–1512PubMedCrossRefGoogle Scholar
  64. 64.
    Ogawa T, Kawai M, Matsui T et al (1996) Vasospastic angina in a patient with Fabry’s disease who showed normal coronary angiographic findings. Jpn Circ J 60(5):315–318PubMedCrossRefGoogle Scholar
  65. 65.
    Seino Y, Vyden JK, Philippart M, Rose HB, Nagasawa K (1983) Peripheral hemodynamics in patients with Fabry’s disease. Am Heart J 105(5):783–787PubMedCrossRefGoogle Scholar
  66. 66.
    Stemper B, Hilz MJ (2003) Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol 250(8):970–976PubMedCrossRefGoogle Scholar
  67. 67.
    Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257(1–2):258–263PubMedCrossRefGoogle Scholar
  68. 68.
    Shirai T, Ohtake T, Kimura M et al (2000) Atypical Fabry’s disease presenting with cholesterol crystal embolization. Intern Med 39(8):646–649PubMedCrossRefGoogle Scholar
  69. 69.
    Schiffmann R, Rapkiewicz A, Abu-Asab M et al (2006) Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 448(3):337–343PubMedCrossRefGoogle Scholar
  70. 70.
    Vedder AC, Gerdes VE, Poorthuis BJ et al (2007) Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males. J Inherit Metab Dis 30(6):988PubMedCrossRefGoogle Scholar
  71. 71.
    Jardine DL, Fitzpatrick MA, Troughton WD, Tie AB (1994) Small bowel ischaemia in Fabry’s disease. J Gastroenterol Hepatol 9(2):201–204PubMedCrossRefGoogle Scholar
  72. 72.
    Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME (1992) Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med 117(3):221–223PubMedGoogle Scholar
  73. 73.
    Orteu CH, Jansen T, Lidove O et al (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157(2):331–337PubMedCrossRefGoogle Scholar
  74. 74.
    Amann-Vesti BR, Gitzelmann G, Widmer U, Bosshard NU, Steinmann B, Koppensteiner R (2003) Severe lymphatic microangiopathy in Fabry disease. Lymphat Res Biol 1(3):185–189PubMedCrossRefGoogle Scholar
  75. 75.
    Wallace RD, Cooper WJ (1965) Angiokeratoma corporis diffusum universale (Fabry). Am J Med 39(4):656–661PubMedCrossRefGoogle Scholar
  76. 76.
    Le Bodic MF, Le Bodic L, Buzelin F, Bureau B, Mussini-Montpellier J (1978) Vascular lesions of Fabry’s disease. Optical, histochemical and ultrastructural studies. Ann Anat Pathol (Paris) 23(1):23–39Google Scholar
  77. 77.
    Kang WH, Chun SI, Lee S (1987) Generalized anhidrosis associated with Fabry’s disease. J Am Acad Dermatol 17(5 Pt 2):883–887PubMedCrossRefGoogle Scholar
  78. 78.
    Lao LM, Kumakiri M, Mima H et al (1998) The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 18(2):109–117PubMedCrossRefGoogle Scholar
  79. 79.
    Nakamura T, Kaneko H, Nishino I (1981) Angiokeratoma corporis diffusum (Fabry disease): ultrastructural studies of the skin. Acta Derm Venereol 61(1):37–41PubMedGoogle Scholar
  80. 80.
    Idoate MA, Pardo-Mindan FJ, Gonzalez Alamillo C (1992) Fabry’s disease without angiokeratomas showing unusual eccrine gland vacuolation. J Pathol 167(1):65–68PubMedCrossRefGoogle Scholar
  81. 81.
    Lidove O, Ramaswami U, Jaussaud R et al (2006) Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract 60(9):1053–1059PubMedCrossRefGoogle Scholar
  82. 82.
    Clarke JT, Knaack J, Crawhall JC, Wolfe LS (1971) Ceramide trihexosidosis (Fabry’s disease) without skin lesions. N Engl J Med 284(5):233–235PubMedCrossRefGoogle Scholar
  83. 83.
    Kanekura T, Fukushige T, Kanda A et al (2005) Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease. Br J Dermatol 153(3):544–548PubMedCrossRefGoogle Scholar
  84. 84.
    Kanitakis J, Allombert C, Doebelin B et al (2005) Fucosidosis with angiokeratoma. Immunohistochemical & electronmicroscopic study of a new case and literature review. J Cutan Pathol 32(7):506–511PubMedCrossRefGoogle Scholar
  85. 85.
    Braverman IM, Ken-Yen A (1983) Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol 81(6):489–497PubMedCrossRefGoogle Scholar
  86. 86.
    Kelly B, Kelly E (2006) Angiokeratoma corporis diffusum in a patient with no recognizable enzyme abnormalities. Arch Dermatol 142(5):615–618PubMedCrossRefGoogle Scholar
  87. 87.
    Burda CD, Winder PR (1967) Angiokeratoma corporis diffusum universale (Fabry’s disease) in female subjects. Am J Med 42(2):293–301PubMedCrossRefGoogle Scholar
  88. 88.
    Handa Y, Yotsumoto S, Isobe E et al (2000) A case of symptomatic heterozygous femaleFabry’s disease without detectable mutation in the alpha-galactosidase gene. Dermatology 200(3):262–265PubMedCrossRefGoogle Scholar
  89. 89.
    Morais P, Santos AL, Baudrier T, Mota AV, Oliveira JP, Azevedo F (2008) Angiokeratomas of Fabry successfully treated with intense pulsed light. J Cosmet Laser Ther 10(4):218–222PubMedCrossRefGoogle Scholar
  90. 90.
    Voglino A, Paradisi M, Dompe G, Onetti Muda A, Faraggiana T (1988) Angiokeratoma corporis diffusum (Fabry’s disease) with unusual features in a female patient. Light-and electron-microscopic investigation. Am J Dermatopathol 10(4):343–348PubMedCrossRefGoogle Scholar
  91. 91.
    Barile L, Messina E, Giacomello A, Marban E (2007) Endogenous cardiac stem cells. Prog Cardiovasc Dis 50(1):31–48PubMedCrossRefGoogle Scholar
  92. 92.
    Liu J, Sluijter JP, Goumans MJ et al (2009) Cell therapy for myocardial regeneration. Curr Mol Med 9(3):287–298PubMedCrossRefGoogle Scholar
  93. 93.
    Thijssen DH, Torella D, Hopman MT, Ellison GM (2009) The role of endothelial progenitor and cardiac stem cells in the cardiovascular adaptations to age and exercise. Front Biosci 14:4685–4702PubMedCrossRefGoogle Scholar
  94. 94.
    Gilbert-Barness E (2004) Review: metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci 34(1):15–34PubMedGoogle Scholar
  95. 95.
    Elleder M, Bradova V, Smid F et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417(5):449–455PubMedCrossRefGoogle Scholar
  96. 96.
    Chimenti C, Hamdani N, Boontje NM et al (2008) Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 172(6):1482–1490PubMedCrossRefGoogle Scholar
  97. 97.
    Davies MJ (1984) The cardiomyopathies: a review of terminology, pathology and pathogenesis. Histopathology 8(3):363–393PubMedCrossRefGoogle Scholar
  98. 98.
    Sheppard MN, Cane P, Florio R et al (2009) A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc PatholGoogle Scholar
  99. 99.
    Bishop JE, Laurent GJ (1995) Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 16(Suppl C):38–44PubMedCrossRefGoogle Scholar
  100. 100.
    Pelouch V, Dixon IM, Golfman L, Beamish RE, Dhalla NS (1993) Role of extracellular matrix proteins in heart function. Mol Cell Biochem 129(2):101–120PubMedCrossRefGoogle Scholar
  101. 101.
    Weber KT, Sun Y, Tyagi SC, Cleutjens JP (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 26(3):279–292PubMedCrossRefGoogle Scholar
  102. 102.
    Ikeda K, Tojo K, Udagawa T et al (2008) Cellular physiology of rat cardiac myocytes in cardiac fibrosis: in vitro simulation using the cardiac myocyte/cardiac non-myocyte co-culture system. Hypertens Res 31(4):693–706PubMedCrossRefGoogle Scholar
  103. 103.
    Kawano M, Takenaka T, Otsuji Y et al (2007) Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry’s disease. Am J Cardiol 99(2):261–263PubMedCrossRefGoogle Scholar
  104. 104.
    Moon JC, Sachdev B, Elkington AG et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24(23):2151–2155PubMedCrossRefGoogle Scholar
  105. 105.
    Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8(3):479–482PubMedCrossRefGoogle Scholar
  106. 106.
    Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson- Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28(10):1228–1235PubMedCrossRefGoogle Scholar
  107. 107.
    Bannwart F (1982) Fabry’s disease. Light and electron microscopic cardiac findings 12 years after successful kidney transplantation. Schweiz Med Wochenschr 112(48):1742–1747PubMedGoogle Scholar
  108. 108.
    Becker AE, Schoorl R, Balk AG, van der Heide RM (1975) Cardiac manifestations of Fabry’s disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 36(6):829–835PubMedCrossRefGoogle Scholar
  109. 109.
    Ikari Y, Kuwako K, Yamaguchi T (1992) Fabry’s disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J 68(3):323–325PubMedCrossRefGoogle Scholar
  110. 110.
    Rumyantsev PP, Erokhina IL, Antipanova EM, Martynova MG (1990) DNA and sex chromatin content in nuclei of conductive system and working myocytes of normal and hypertrophied human heart. Acta Histochem Suppl 39:225–237PubMedGoogle Scholar
  111. 111.
    Matsui S, Murakami E, Takekoshi N, Hiramaru Y, Kin T (1977) Cardiac manifestations of Fabry’s disease. Report of a case with pulmonary regurgitation diagnosed on the basis of endomyocardial biopsy findings. Jpn Circ J 41(9):1023–1036PubMedCrossRefGoogle Scholar
  112. 112.
    Choi S, Seo H, Park M et al (2009) Fabry disease with aortic regurgitation. Ann Thorac Surg 87(2):625–628PubMedCrossRefGoogle Scholar
  113. 113.
    Leder AA, Bosworth WC (1965) Angiokeratoma Corporis Diffusum Universale (Fabry’s Disease) with Mitral Stenosis. Am J Med 38:814–819PubMedCrossRefGoogle Scholar
  114. 114.
    Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH (1976) Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 54(5):818–825PubMedCrossRefGoogle Scholar
  115. 115.
    Ferrans VJ, Hibbs RG, Burda CD (1969) The heart in Fabry’s disease. A histochemical and electron microscopic study. Am J Cardiol 24(1):95–110CrossRefGoogle Scholar
  116. 116.
    Bass JL, Shrivastava S, Grabowski GA, Desnick RJ, Moller JH (1980) The M-mode echocardiogram in Fabry’s disease. Am Heart J 100(6 Pt 1):807–812PubMedCrossRefGoogle Scholar
  117. 117.
    Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ (1986) Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol 7(5):1157–1161PubMedCrossRefGoogle Scholar
  118. 118.
    Chimenti C, Pieroni M, Morgante E et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110(9):1047–1053PubMedCrossRefGoogle Scholar
  119. 119.
    Ogawa K, Abe T, Yoshimura K, Nagashima K, Nagashima T (1985) Cardiac accumulation of trihexosylceramide in a case with amyotrophic lateral sclerosis. Jpn J Exp Med 55(3):123–127PubMedGoogle Scholar
  120. 120.
    von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324(6):395–399CrossRefGoogle Scholar
  121. 121.
    Nakao S, Kodama C, Takenaka T et al (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 64(3):801–807PubMedCrossRefGoogle Scholar
  122. 122.
    Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134–S138PubMedGoogle Scholar
  123. 123.
    Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int 13(3):223–235PubMedCrossRefGoogle Scholar
  124. 124.
    Barisoni L, Schnaper HW, Kopp JB (2009) Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med 133(2):201–216PubMedGoogle Scholar
  125. 125.
    Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19(10):1295–1301PubMedCrossRefGoogle Scholar
  126. 126.
    Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R (1973) Renal pathologic lesions and functional alterations in a man with Fabry’s disease. Am J Med 55(3):415–425PubMedCrossRefGoogle Scholar
  127. 127.
    Parchoux B, Guibaud P, Maire I et al (1978) Fabry’s disease. Initial nephrogenic diabetes insipidus in children. Pediatrie 33(8):757–765PubMedGoogle Scholar
  128. 128.
    Wornell P, Dyack S, Crocker J, Yu W, Acott P (2006) Fabry disease and nephrogenic diabetes insipidus. Pediatr Nephrol 21(8):1185–1188PubMedCrossRefGoogle Scholar
  129. 129.
    Mills K, Morris P, Lee P et al (2005) Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 28(1):35–48PubMedCrossRefGoogle Scholar
  130. 130.
    Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry’s disease. Ann Neurol 40(1):8–17PubMedCrossRefGoogle Scholar
  131. 131.
    Nill M, Muller MJ, Beck M, Stoeter P, Fellgiebel A (2006) Pathophysiological aspects of brain structural disturbances in patients with Fabry disease: literature review. Fortschr Neurol Psychiatr 74(12):687–695PubMedCrossRefGoogle Scholar
  132. 132.
    Fellgiebel A, Muller MJ, Ginsberg L (2006) CNS manifestations of Fabry’s disease. Lancet Neurol 5(9):791–795PubMedCrossRefGoogle Scholar
  133. 133.
    Gadoth N, Sandbank U (1983) Involvement of dorsal root ganglia in Fabry’s disease. J Med Genet 20(4):309–312PubMedCrossRefGoogle Scholar
  134. 134.
    Onishi A, Dyck PJ (1974) Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol 31(2):120–127PubMedCrossRefGoogle Scholar
  135. 135.
    Gemignani F, Marbini A, Bragaglia MM, Govoni E (1984) Pathological study of the sural nerve in Fabry’s disease. Eur Neurol 23(3):173–181PubMedCrossRefGoogle Scholar
  136. 136.
    Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19(6):575–586PubMedCrossRefGoogle Scholar
  137. 137.
    Vital A, Vital C, Maleville J (1984) Fabry’s disease: an ultrastructural study of muscle and peripheral nerve. Clin Neuropathol 3(4):168–172PubMedGoogle Scholar
  138. 138.
    Fukuhara N, Suzuki M, Fujita N, Tsubaki T (1975) Fabry’s disease on the mechanism of the peripheral nerve involvement. Acta Neuropathol 33(1):9–21PubMedCrossRefGoogle Scholar
  139. 139.
    Cable WJ, Dvorak AM, Osage JE, Kolodny EH (1982) Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. Neurology 32(4):347–353PubMedCrossRefGoogle Scholar
  140. 140.
    Tabira T, Goto I, Kuroiwa Y, Kikuchi M (1974) Neuropathological and biochemical studies in Fabry’s disease. Acta Neuropathol 30(4):345–354PubMedCrossRefGoogle Scholar
  141. 141.
    Grunnet ML, Spilsbury PR (1973) The central nervous system in Fabry’s disease. An ultrastructural study. Arch Neurol 28(4):231–234PubMedCrossRefGoogle Scholar
  142. 142.
    Kaye EM, Kolodny EH, Logigian EL, Ullman MD (1988) Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol 23(5):505–509PubMedCrossRefGoogle Scholar
  143. 143.
    Rahman AN, Lindenberg R (1963) The Neuropathology of hereditary dystopic lipidosis. Arch Neurol 9:373–385PubMedCrossRefGoogle Scholar
  144. 144.
    Schibanoff JM, Kamoshita S, O’Brien JS (1969) Tissue distribution of glycosphingolipids in a case of Fabry’s disease. J Lipid Res 10(5):515–520PubMedGoogle Scholar
  145. 145.
    Riegel EM, Pokorny KS, Friedman AH, Suhan J, Ritch RH, Desnick RJ (1982) Ocular pathology of Fabry’s disease in a hemizygous male following renal transplantation. Surv Ophthalmol 26(5):247–252PubMedCrossRefGoogle Scholar
  146. 146.
    Moore DF, Gelderman MP, Fuhrmann SR, Schiffmann R, Brady RO, Goldin E (2006) Fabry disease and vascular risk factors: future strategies for patient-based studies and the knockout murine model. Acta Paediatr Suppl 95(451):69–71PubMedCrossRefGoogle Scholar
  147. 147.
    Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 67(11):2045–2047PubMedCrossRefGoogle Scholar
  148. 148.
    Haebara H, Hasama F, Amano A (1975) Neural involvement in Fabry´s disease. In: Körney S, Tariska S, Gosztonyi G (eds) 7th congress of neuropathology. Akadémici Kiadó, Budapest, pp 263–266Google Scholar
  149. 149.
    Sung JH, Hayano M, Mastri AR, Desnick R (1975) Neuropathology of Fabry´s disease. In: Körney S, Tariska S, Gozstonyi G (eds) 7th congress of neuropathology. Akadémici Kiadó, BudapestGoogle Scholar
  150. 150.
    Mazurova Y, Rudolf E, Latr I, Osterreicher J (2006) Proliferation and differentiation of adult endogenous neural stem cells in response to neurodegenerative process within the striatum. Neurodegener Dis 3(1–2):12–18PubMedGoogle Scholar
  151. 151.
    Elleder M, Christomanou H, Kustermann-Kuhn B, Harzer K (1994) Leptomeningeal lipid storage patterns in Fabry disease. Acta Neuropathol 88(6):579–582PubMedCrossRefGoogle Scholar
  152. 152.
    Lou HO, Reske-Nielsen E (1971) the central nervous system in Fabry’s disease. A clinical, pathological, and biochemical investigation. Arch Neurol 25(4):351–359PubMedCrossRefGoogle Scholar
  153. 153.
    Tagliavini F, Pietrini V, Gemignani F, Lechi A, Pallini R, Federico A (1982) Anderson-Fabry’s disease: neuropathological and neurochemical investigation. Acta Neuropathol 56(2):93–98PubMedCrossRefGoogle Scholar
  154. 154.
    Bartimmo EE Jr, Guisan M, Moser KM (1972) Pulmonary involvement in Fabry’s disease: a reappraisal follow-up of a San Diego kindred and review of literature. Am J Med 53(6):755–764PubMedCrossRefGoogle Scholar
  155. 155.
    Brown LK, Miller A, Bhuptani A et al (1997) Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 155(3):1004–1010PubMedGoogle Scholar
  156. 156.
    Magage S, Lubanda JC, Susa Z et al (2007) Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis 30(5):790–799PubMedCrossRefGoogle Scholar
  157. 157.
    Smith P, Heath D, Rodgers B, Helliwell T (1991) Pulmonary vasculature in Fabry’s disease. Histopathology 19(6):567–569PubMedCrossRefGoogle Scholar
  158. 158.
    Elleder M (1985) Fabry’s disease: absence of storage as a feature of liver sinus endothelium. Acta Histochem 77(1):33–36PubMedCrossRefGoogle Scholar
  159. 159.
    Meuwissen SG, Dingemans KP, Strijland A, Tager JM, Ooms BC (1982) Ultrastructural and biochemical liver analyses in Fabry’s disease. Hepatology 2(2):263–268PubMedCrossRefGoogle Scholar
  160. 160.
    Prasad R (2008) Abdominal viscera liver. In: Standring S (ed) Gray´s anatomy the anatomocal basis of clinical practice, 40th edn. Churchill Livingstone, Elsevier, London, pp 1163–1176Google Scholar
  161. 161.
    Roland D, Dehout F, van Maldergem L (2003) Fabry disease – gastrointestinal symptoms, renal aspects, neurological and ocular manifestations. Acta Paediatrica Suppl 443:110–115Google Scholar
  162. 162.
    Goodwin SE, Richfield L, Milligan A, Mehta A (2003) Gastrointestinal symptoms in patients with Fabry disease and their response to pancreatin supplements. Acta Paediatr Suppl 443:110–115Google Scholar
  163. 163.
    Flynn DM, Lake BD, Boothby CB, Young EP (1972) Gut lesions in Fabry’s disease without a rash. Arch Dis Child 47(251):26–33PubMedCrossRefGoogle Scholar
  164. 164.
    Rowe JW, Gilliam JI, Warthin TA (1974) Intestinal manifestations of Fabry’s disease. Ann Intern Med 81(5):628–631PubMedGoogle Scholar
  165. 165.
    Keshav S (2006) Gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry diseas Perspectives from 5 years of FOS, 1st edn. Oxford Pharma Genesis Ltd, Oxford, pp 271–279Google Scholar
  166. 166.
    Jack CI, Morris AI, Nasmyth DG, Carroll N (1991) Colonic involvement in Fabry’s disease. Postgrad Med J 67(788):584–585PubMedCrossRefGoogle Scholar
  167. 167.
    O’Brien BD, Shnitka TK, McDougall R et al (1982) Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry’s disease. Gastroenterology 82(5 Pt 1):957–962PubMedGoogle Scholar
  168. 168.
    Sheth KJ, Werlin SL, Freeman ME, Hodach AE (1981) Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol 76(3):246–251PubMedGoogle Scholar
  169. 169.
    Roth J, Roth H (1978) Electron microscopic observations in internal organs in morbus Fabry (author’s transl). Virchows Arch A Pathol Anat Histol 378(1):75–90PubMedCrossRefGoogle Scholar
  170. 170.
    Hegemann S, Hajioff D, Conti G et al (2006) Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36(9):654–662PubMedCrossRefGoogle Scholar
  171. 171.
    Keilmann A (2003) Inner ear function in children with Fabry disease. Acta Paediatr Suppl 92(443):31–32, discussion 27PubMedGoogle Scholar
  172. 172.
    Schachern PA, Shea DA, Paparella MM, Yoon TH (1989) Otologic histopathology of Fabry’s disease. Ann Otol Rhinol Laryngol 98(5 Pt 1):359–363PubMedGoogle Scholar
  173. 173.
    Sergi B, Conti G (2007) Hearing loss in a family affected by Fabry disease. J Inherit MetabDis 30(3):370–374CrossRefGoogle Scholar
  174. 174.
    Malinvaud D, Lecanu JB, Halimi P, Avan P, Bonfils P (2006) Tinnitus and cerebellar developmental venous anomaly. Arch Otolaryngol Head Neck Surg 132(5):550–553PubMedCrossRefGoogle Scholar
  175. 175.
    Ries M, Kim HJ, Zalewski CK et al (2007) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130(Pt 1):143–150PubMedGoogle Scholar
  176. 176.
    Conti G, Sergi B (2003) Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr Suppl 92(443):33–37, discussion 27PubMedGoogle Scholar
  177. 177.
    Palla A, Widmer U, Straumann D (2003) Head-impulse testing in Fabry disease–vestibular function in male and female patients. Acta Paediatr Suppl 92(443):38–42, discussion 27PubMedGoogle Scholar
  178. 178.
    Noben-Trauth K, Neely H, Brady RO (2007) Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for Fabry disease. Hear Res 234(1–2):10–14PubMedCrossRefGoogle Scholar
  179. 179.
    Guo YK, Xie DH, Yang XM (2005) Morphological and functional alterations of ear in lysosomal neuraminidase gene deficient mouse. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 40(11):824–829PubMedGoogle Scholar
  180. 180.
    Coenen R, Gieselmann V, Lullmann-Rauch R (2001) Morphological alterations in the inner ear of the arylsulfatase A-deficient mouse. Acta Neuropathol 101(5):491–498PubMedGoogle Scholar
  181. 181.
    Schachern PA, Cureoglu S, Tsuprun V, Paparella MM, Whitley CB (2007) Age-related functional and histopathological changes of the ear in the MPS I mouse. Int J Pediatr Otorhinolaryngol 71(2):197–203PubMedCrossRefGoogle Scholar
  182. 182.
    Elleder M, Voldrich L, Ulehlova L, Dimitt S, Armstrong D (1988) Light and electron microscopic appearance of the inner ear in juvenile ceroid lipofuscinosis (CL). Pathol Res Pract 183(3):301–307PubMedCrossRefGoogle Scholar
  183. 183.
    Macrae WG, Ghosh M, McCulloch C (1985) Corneal changes in Fabry’s disease: a clinico-pathologic case report of a heterozygote. Ophthalmic Paediatr Genet 5(3):185–190PubMedCrossRefGoogle Scholar
  184. 184.
    Font RL, Fine BS (1972) Ocular pathology in Fabry’s disease. Histochemical and electron microscopic observations. Am J Ophthalmol 73(3):419–430PubMedGoogle Scholar
  185. 185.
    Tripathi RC, Ashton N (1976) Application of electron microscopy to the study of ocular inborn errors of metabolism. Birth Defects Orig Artic Ser 12(3):69–104PubMedGoogle Scholar
  186. 186.
    Francois J, Hanssens M, Teuchy H (1978) Corneal ultrastructural changes in Fabry’s disease. Ophthalmologica 176(6):313–330PubMedCrossRefGoogle Scholar
  187. 187.
    Weingeist TA, Blodi FC (1971) Fabry’s disease: ocular findings in a female carrier. A light and electron microscopy study. Arch Ophthalmol 85(2):169–176PubMedCrossRefGoogle Scholar
  188. 188.
    Falke K, Buttner A, Schittkowski M et al (2009) The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. Graefes Arch Clin Exp Ophthalmol 247(4):523–534PubMedCrossRefGoogle Scholar
  189. 189.
    Mastropasqua L, Nubile M, Lanzini M, Carpineto P, Toto L, Ciancaglini M (2006) Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study. Am J Ophthalmol 141(4):709–718PubMedCrossRefGoogle Scholar
  190. 190.
    Hirano K, Murata K, Miyagawa A et al (2001) Histopathologic findings of cornea verticillata in a woman heterozygous for Fabry’s disease. Cornea 20(2):233–236PubMedCrossRefGoogle Scholar
  191. 191.
    Standring S (2008) The eye. In: Standring S (ed) Gray´s anatomy, 40th edn. Elsevier, London, pp 675–703Google Scholar
  192. 192.
    Libert J, Tondeur M, Van Hoof F (1976) The use of conjunctival biopsy and enzyme analysis in tears for the diagnosis of homozygotes and heterozygotes with Fabry disease. Birth Defects Orig Artic Ser 12(3):221–239PubMedGoogle Scholar

Copyright information

© Springer Netherlands 2010

Authors and Affiliations

  1. 1.First Faculty of MedicineInstitute of Inherited Metabolic Disorders, Charles UniversityPragueCzech Republic

Personalised recommendations